Evan Minkoff, DO
Sports Medicine · Rancho Mirage, CANPI 1831150739
Payments from drug & device makers
Across 165 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- Scilex Pharmaceuticals Inc.$220
- Forte Bio-pharma LLC$203
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$166
- Virtus Pharmaceuticals LLC$148
- Valinor Pharma, LLC$133
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 72 | $1,320 |
| Scilex Pharmaceuticals Inc. | 11 | $220 |
| Forte Bio-pharma LLC | 11 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $166 |
| Virtus Pharmaceuticals LLC | 7 | $148 |
| Valinor Pharma, LLC | 7 | $133 |
| Boston Scientific | 4 | $130 |
| Vertex | 3 | $76 |
| Sentynl Therapeutics, Inc. | 5 | $73 |
| Almatica Pharma LLC | 4 | $70 |
| GRT US Holding, Inc. | 2 | $63 |
| Nevro Corp. | 3 | $57 |
| Abbott | 3 | $55 |
| Medtronic(2 entities) | 2 | $55 |
| AbbVie(2 entities) | 3 | $55 |
| Fidia Pharma USA Inc. | 2 | $50 |
| Averitas Pharma Inc. | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Redhill Biopharma Inc. | 2 | $34 |
| Amgen | 2 | $29 |
| Avanos Medical | 1 | $24 |
| Bioventus LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Si-bone, Inc. | 1 | $17 |
| Stratus Medical, LLC | 1 | $14 |
| Vertos Medical, Inc. | 1 | $12 |
How this compares
$3,203 in reported general payments places this provider in the 55th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 15 | $10,369 |
| MovantikNaloxegol Oxalate | 12 | $4,625 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 206 | $4,033 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 81 | $1,599 |
| Methocarbamol | 27 | $554 |
| Gabapentin | 39 | $531 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $469 |
| Cyclobenzaprine Hcl | 41 | $288 |
| Ibuprofen | 29 | $183 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $157 |
| Diclofenac Sodium | 18 | $137 |
| Duloxetine Hcl | 12 | $133 |
| Oxycodone Hcl | 21 | $105 |
| Tramadol Hcl | 33 | $74 |
| Naproxen | 18 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $1,320 | $10,36915 claims |
| Redhill Biopharma Inc.Movantik | $34 | $4,62512 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $19 | $46913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 662 sports medicine providers in California.
Other sports medicine in Rancho Mirage
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Marc SafranPalo Alto$1.2M
- Stephan YacoubianBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.